Compare IDYA & CC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDYA | CC |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.3B |
| IPO Year | 2019 | N/A |
| Metric | IDYA | CC |
|---|---|---|
| Price | $33.38 | $11.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | ★ $49.42 | $17.00 |
| AVG Volume (30 Days) | 926.1K | ★ 2.5M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 2.70% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $214,834,000.00 | ★ $5,837,000,000.00 |
| Revenue This Year | $2,434.86 | $3.34 |
| Revenue Next Year | N/A | $4.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5377.66 | 0.03 |
| 52 Week Low | $13.45 | $9.13 |
| 52 Week High | $37.08 | $20.12 |
| Indicator | IDYA | CC |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 43.69 |
| Support Level | $33.12 | $12.09 |
| Resistance Level | $37.08 | $13.42 |
| Average True Range (ATR) | 1.47 | 0.66 |
| MACD | -0.36 | 0.09 |
| Stochastic Oscillator | 6.82 | 21.52 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.